News und Analysen
![Poxel Reports Financial Results for Full Year 2021 and Provides Corporate Update: https://mms.businesswire.com/media/20210929005940/en/578635/5/POXEL_LOGO_Q.jpg](https://www.sharewise.com/rails/active_storage/representations/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaHBBOTA1Vnc9PSIsImV4cCI6bnVsbCwicHVyIjoiYmxvYl9pZCJ9fQ==--a443757a54f31cbfc57d9b7b8b30d0d59fbe9bd4/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaDdCam9MY21WemFYcGxTU0lKTXpVd2VBWTZCa1ZVIiwiZXhwIjpudWxsLCJwdXIiOiJ2YXJpYXRpb24ifX0=--aa36f503a05c343bf077379e5dc8bce118d9db18/POXEL_LOGO_Q.jpg?locale=de)
Poxel Reports Financial Results for Full Year 2021 and Provides Corporate Update
POXEL SA (Euronext: POXEL - FR0012432516), a clinical stage biopharmaceutical company developing innovative treatments for serious chronic diseases with metabolic pathophysiology, including
![NANOBIOTIX to Announce Full Year 2021 Financial Results on March 30, 2022: https://mms.businesswire.com/media/20191111005579/en/744572/5/LOGO_NANO_EXPANDING_LIFE.jpg](https://www.sharewise.com/rails/active_storage/representations/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaHBBM25oRUE9PSIsImV4cCI6bnVsbCwicHVyIjoiYmxvYl9pZCJ9fQ==--fb25377a8ea9e69d3b62f03b482ed70fb95efba1/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaDdCam9MY21WemFYcGxTU0lKTXpVd2VBWTZCa1ZVIiwiZXhwIjpudWxsLCJwdXIiOiJ2YXJpYXRpb24ifX0=--aa36f503a05c343bf077379e5dc8bce118d9db18/LOGO_NANO_EXPANDING_LIFE.jpg?locale=de)
NANOBIOTIX to Announce Full Year 2021 Financial Results on March 30, 2022
NANOBIOTIX (Euronext: NANO – NASDAQ: NBTX – the ‘‘Company’’) (Paris:NANO) (NASDAQ:NBTX), a late-stage clinical biotechnology company pioneering physics-based approaches to expand treatment
![Transgene Confirms the Potential of Its Two Innovative Platforms and Expects Significant Clinical Results in 2022: https://mms.businesswire.com/media/20191209005543/en/255636/5/logo_TRANSGENE.jpg](https://www.sharewise.com/rails/active_storage/representations/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaHBBOFo2Rmc9PSIsImV4cCI6bnVsbCwicHVyIjoiYmxvYl9pZCJ9fQ==--73fe07bc16ac0607e1cc0e1a0b34e650fa94b07d/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaDdCam9MY21WemFYcGxTU0lKTXpVd2VBWTZCa1ZVIiwiZXhwIjpudWxsLCJwdXIiOiJ2YXJpYXRpb24ifX0=--aa36f503a05c343bf077379e5dc8bce118d9db18/logo_TRANSGENE.jpg?locale=de)
Transgene Confirms the Potential of Its Two Innovative Platforms and Expects Significant Clinical Results in 2022
Regulatory News:
Transgene (Euronext Paris: TNG) (Paris:TNG), a biotech company that designs and develops virus-based immunotherapies for the treatment of cancer, today publishes its financial
![Poxel to Report Financial Results for Full Year 2021 and Host Webcast Call on March 22, 2022: https://mms.businesswire.com/media/20210929005940/en/578635/5/POXEL_LOGO_Q.jpg](https://www.sharewise.com/rails/active_storage/representations/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaHBBOTA1Vnc9PSIsImV4cCI6bnVsbCwicHVyIjoiYmxvYl9pZCJ9fQ==--a443757a54f31cbfc57d9b7b8b30d0d59fbe9bd4/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaDdCam9MY21WemFYcGxTU0lKTXpVd2VBWTZCa1ZVIiwiZXhwIjpudWxsLCJwdXIiOiJ2YXJpYXRpb24ifX0=--aa36f503a05c343bf077379e5dc8bce118d9db18/POXEL_LOGO_Q.jpg?locale=de)
Poxel to Report Financial Results for Full Year 2021 and Host Webcast Call on March 22, 2022
POXEL SA (Euronext: POXEL - FR0012432516), a clinical stage biopharmaceutical company developing innovative treatments for chronic serious diseases with metabolic pathophysiology, including
![Transgene to Present New Positive Preliminary Phase I Data on TG4050 (myvac® platform), its Individualized Therapeutic Cancer Vaccine, at AACR 2022: https://mms.businesswire.com/media/20191209005543/en/255636/5/logo_TRANSGENE.jpg](https://www.sharewise.com/rails/active_storage/representations/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaHBBOFo2Rmc9PSIsImV4cCI6bnVsbCwicHVyIjoiYmxvYl9pZCJ9fQ==--73fe07bc16ac0607e1cc0e1a0b34e650fa94b07d/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaDdCam9MY21WemFYcGxTU0lKTXpVd2VBWTZCa1ZVIiwiZXhwIjpudWxsLCJwdXIiOiJ2YXJpYXRpb24ifX0=--aa36f503a05c343bf077379e5dc8bce118d9db18/logo_TRANSGENE.jpg?locale=de)
Transgene to Present New Positive Preliminary Phase I Data on TG4050 (myvac® platform), its Individualized Therapeutic Cancer Vaccine, at AACR 2022
Regulatory News:
Transgene (Euronext Paris: TNG) (Paris:TNG), a biotech company that designs and develops virus-based immunotherapies for the treatment of cancer will be presenting a poster with
![Transgene and BioInvent Announce Poster Presentation on BT-001, a Novel Antibody-encoding Oncolytic Virus, at AACR 2022: https://mms.businesswire.com/media/20191209005543/en/255636/5/logo_TRANSGENE.jpg](https://www.sharewise.com/rails/active_storage/representations/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaHBBOFo2Rmc9PSIsImV4cCI6bnVsbCwicHVyIjoiYmxvYl9pZCJ9fQ==--73fe07bc16ac0607e1cc0e1a0b34e650fa94b07d/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaDdCam9MY21WemFYcGxTU0lKTXpVd2VBWTZCa1ZVIiwiZXhwIjpudWxsLCJwdXIiOiJ2YXJpYXRpb24ifX0=--aa36f503a05c343bf077379e5dc8bce118d9db18/logo_TRANSGENE.jpg?locale=de)
Transgene and BioInvent Announce Poster Presentation on BT-001, a Novel Antibody-encoding Oncolytic Virus, at AACR 2022
Regulatory News:
Transgene (Euronext Paris: TNG), a biotech company that designs and develops virus-based immunotherapeutics against cancer, and BioInvent International AB (“BioInvent”) (Nasdaq
![Nanobiotix: Statement of Total Voting Rights and Shares Forming the Company’s Share Capital: https://mms.businesswire.com/media/20191111005579/en/744572/5/LOGO_NANO_EXPANDING_LIFE.jpg](https://www.sharewise.com/rails/active_storage/representations/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaHBBM25oRUE9PSIsImV4cCI6bnVsbCwicHVyIjoiYmxvYl9pZCJ9fQ==--fb25377a8ea9e69d3b62f03b482ed70fb95efba1/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaDdCam9MY21WemFYcGxTU0lKTXpVd2VBWTZCa1ZVIiwiZXhwIjpudWxsLCJwdXIiOiJ2YXJpYXRpb24ifX0=--aa36f503a05c343bf077379e5dc8bce118d9db18/LOGO_NANO_EXPANDING_LIFE.jpg?locale=de)
Nanobiotix: Statement of Total Voting Rights and Shares Forming the Company’s Share Capital
Regulatory News:
Nanobiotix (Paris:NANO) (NASDAQ:NBTX):
Market: Euronext Paris / Nasdaq
Euronext Compartment: B
ISIN code: FR0011341205
Nasdaq: NBTX
Bloomberg: NANO:FP
Reuters: NANO.PA
Website
![Poxel Announces PXL065 Granted FDA Fast Track Designation for X-linked Adrenoleukodystrophy: https://mms.businesswire.com/media/20210929005940/en/578635/5/POXEL_LOGO_Q.jpg](https://www.sharewise.com/rails/active_storage/representations/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaHBBOTA1Vnc9PSIsImV4cCI6bnVsbCwicHVyIjoiYmxvYl9pZCJ9fQ==--a443757a54f31cbfc57d9b7b8b30d0d59fbe9bd4/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaDdCam9MY21WemFYcGxTU0lKTXpVd2VBWTZCa1ZVIiwiZXhwIjpudWxsLCJwdXIiOiJ2YXJpYXRpb24ifX0=--aa36f503a05c343bf077379e5dc8bce118d9db18/POXEL_LOGO_Q.jpg?locale=de)
Poxel Announces PXL065 Granted FDA Fast Track Designation for X-linked Adrenoleukodystrophy
POXEL SA (Euronext: POXEL - FR0012432516), a clinical stage biopharmaceutical company developing innovative treatments for serious chronic diseases with metabolic pathophysiology, including
![Poxel Reports Financial Update for Cash and Revenue for the Full Year 2021 and Provides Corporate Update: https://mms.businesswire.com/media/20210929005940/en/578635/5/POXEL_LOGO_Q.jpg](https://www.sharewise.com/rails/active_storage/representations/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaHBBOTA1Vnc9PSIsImV4cCI6bnVsbCwicHVyIjoiYmxvYl9pZCJ9fQ==--a443757a54f31cbfc57d9b7b8b30d0d59fbe9bd4/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaDdCam9MY21WemFYcGxTU0lKTXpVd2VBWTZCa1ZVIiwiZXhwIjpudWxsLCJwdXIiOiJ2YXJpYXRpb24ifX0=--aa36f503a05c343bf077379e5dc8bce118d9db18/POXEL_LOGO_Q.jpg?locale=de)
Poxel Reports Financial Update for Cash and Revenue for the Full Year 2021 and Provides Corporate Update
POXEL SA (Euronext: POXEL - FR0012432516), a clinical stage biopharmaceutical company developing innovative treatments for chronic serious diseases with metabolic pathophysiology, including
![Nanobiotix: Statement of Total Voting Rights and Shares Forming the Company’s Share Capital: https://mms.businesswire.com/media/20191111005579/en/744572/5/LOGO_NANO_EXPANDING_LIFE.jpg](https://www.sharewise.com/rails/active_storage/representations/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaHBBM25oRUE9PSIsImV4cCI6bnVsbCwicHVyIjoiYmxvYl9pZCJ9fQ==--fb25377a8ea9e69d3b62f03b482ed70fb95efba1/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaDdCam9MY21WemFYcGxTU0lKTXpVd2VBWTZCa1ZVIiwiZXhwIjpudWxsLCJwdXIiOiJ2YXJpYXRpb24ifX0=--aa36f503a05c343bf077379e5dc8bce118d9db18/LOGO_NANO_EXPANDING_LIFE.jpg?locale=de)
Nanobiotix: Statement of Total Voting Rights and Shares Forming the Company’s Share Capital
Regulatory News:
Nanobiotix (Paris:NANO) (NASDAQ:NBTX):
Market: Euronext Paris / Nasdaq
Euronext Compartment: B
ISIN code: FR0011341205
Nasdaq: NBTX
Bloomberg: NANO:FP
Reuters: NANO.PA
Website
![Transgene Appoints Steven Bloom as Chief Business Officer: https://mms.businesswire.com/media/20191209005543/en/255636/5/logo_TRANSGENE.jpg](https://www.sharewise.com/rails/active_storage/representations/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaHBBOFo2Rmc9PSIsImV4cCI6bnVsbCwicHVyIjoiYmxvYl9pZCJ9fQ==--73fe07bc16ac0607e1cc0e1a0b34e650fa94b07d/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaDdCam9MY21WemFYcGxTU0lKTXpVd2VBWTZCa1ZVIiwiZXhwIjpudWxsLCJwdXIiOiJ2YXJpYXRpb24ifX0=--aa36f503a05c343bf077379e5dc8bce118d9db18/logo_TRANSGENE.jpg?locale=de)
Transgene Appoints Steven Bloom as Chief Business Officer
Regulatory News:
Transgene (Euronext Paris: TNG) (Paris:TNG), a biotech company that designs and develops virus-based immunotherapeutics against cancer, announced today that it has appointed
![Nanobiotix Announces Publication of New Clinical Case Study Highlighting First Patient Experience of NBTXR3 Treatment for Pancreatic Cancer: https://mms.businesswire.com/media/20191111005579/en/744572/5/LOGO_NANO_EXPANDING_LIFE.jpg](https://www.sharewise.com/rails/active_storage/representations/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaHBBM25oRUE9PSIsImV4cCI6bnVsbCwicHVyIjoiYmxvYl9pZCJ9fQ==--fb25377a8ea9e69d3b62f03b482ed70fb95efba1/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaDdCam9MY21WemFYcGxTU0lKTXpVd2VBWTZCa1ZVIiwiZXhwIjpudWxsLCJwdXIiOiJ2YXJpYXRpb24ifX0=--aa36f503a05c343bf077379e5dc8bce118d9db18/LOGO_NANO_EXPANDING_LIFE.jpg?locale=de)
Nanobiotix Announces Publication of New Clinical Case Study Highlighting First Patient Experience of NBTXR3 Treatment for Pancreatic Cancer
Regulatory News:
NANOBIOTIX (Euronext: NANO – NASDAQ: NBTX – the ‘‘Company’’), a late-stage clinical biotechnology company pioneering physics-based approaches to expand treatment possibilities
![NANOBIOTIX Announces Publication of New Preclinical Immunotherapy Data Showcasing the Combination Potential of NBTXR3 With anti-PD-1 and anti-CTLA-4: https://mms.businesswire.com/media/20191111005579/en/744572/5/LOGO_NANO_EXPANDING_LIFE.jpg](https://www.sharewise.com/rails/active_storage/representations/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaHBBM25oRUE9PSIsImV4cCI6bnVsbCwicHVyIjoiYmxvYl9pZCJ9fQ==--fb25377a8ea9e69d3b62f03b482ed70fb95efba1/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaDdCam9MY21WemFYcGxTU0lKTXpVd2VBWTZCa1ZVIiwiZXhwIjpudWxsLCJwdXIiOiJ2YXJpYXRpb24ifX0=--aa36f503a05c343bf077379e5dc8bce118d9db18/LOGO_NANO_EXPANDING_LIFE.jpg?locale=de)
NANOBIOTIX Announces Publication of New Preclinical Immunotherapy Data Showcasing the Combination Potential of NBTXR3 With anti-PD-1 and anti-CTLA-4
Regulatory News:
NANOBIOTIX (Euronext: NANO – NASDAQ: NBTX – the ‘‘Company’’) (Paris:NANO) (NASDAQ:NBTX), a late-stage clinical biotechnology company pioneering physics-based approaches to expand
![Transgene and BioInvent Joint JITC Publication Demonstrates the Potential of BT-001 Oncolytic Virus to Provide Therapeutic Benefit Beyond Current Anti-PD1/ Anti-CTLA-4 Immune Checkpoint Blockade: https://mms.businesswire.com/media/20191209005543/en/255636/5/logo_TRANSGENE.jpg](https://www.sharewise.com/rails/active_storage/representations/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaHBBOFo2Rmc9PSIsImV4cCI6bnVsbCwicHVyIjoiYmxvYl9pZCJ9fQ==--73fe07bc16ac0607e1cc0e1a0b34e650fa94b07d/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaDdCam9MY21WemFYcGxTU0lKTXpVd2VBWTZCa1ZVIiwiZXhwIjpudWxsLCJwdXIiOiJ2YXJpYXRpb24ifX0=--aa36f503a05c343bf077379e5dc8bce118d9db18/logo_TRANSGENE.jpg?locale=de)
Transgene and BioInvent Joint JITC Publication Demonstrates the Potential of BT-001 Oncolytic Virus to Provide Therapeutic Benefit Beyond Current Anti-PD1/ Anti-CTLA-4 Immune Checkpoint Blockade
Regulatory News:
Transgene (Euronext Paris: TNG), a biotech company that designs and develops virus-based immunotherapeutics against cancer, and BioInvent International AB (“BioInvent”) (Nasdaq
![Transgene and PersonGen Announce Collaboration to Evaluate a New Combination Therapy Against Solid Tumors: https://mms.businesswire.com/media/20191209005543/en/255636/5/logo_TRANSGENE.jpg](https://www.sharewise.com/rails/active_storage/representations/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaHBBOFo2Rmc9PSIsImV4cCI6bnVsbCwicHVyIjoiYmxvYl9pZCJ9fQ==--73fe07bc16ac0607e1cc0e1a0b34e650fa94b07d/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaDdCam9MY21WemFYcGxTU0lKTXpVd2VBWTZCa1ZVIiwiZXhwIjpudWxsLCJwdXIiOiJ2YXJpYXRpb24ifX0=--aa36f503a05c343bf077379e5dc8bce118d9db18/logo_TRANSGENE.jpg?locale=de)
Transgene and PersonGen Announce Collaboration to Evaluate a New Combination Therapy Against Solid Tumors
Regulatory News:
Transgene (Euronext Paris: TNG) (Paris:TNG), a biotech company that designs and develops virus-based immunotherapeutics against cancer, and PersonGen BioTherapeutics, a Chinese
![Nanobiotix: Statement of Total Voting Rights and Shares Forming the Company’s Share Capital: https://mms.businesswire.com/media/20191111005579/en/744572/5/LOGO_NANO_EXPANDING_LIFE.jpg](https://www.sharewise.com/rails/active_storage/representations/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaHBBM25oRUE9PSIsImV4cCI6bnVsbCwicHVyIjoiYmxvYl9pZCJ9fQ==--fb25377a8ea9e69d3b62f03b482ed70fb95efba1/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaDdCam9MY21WemFYcGxTU0lKTXpVd2VBWTZCa1ZVIiwiZXhwIjpudWxsLCJwdXIiOiJ2YXJpYXRpb24ifX0=--aa36f503a05c343bf077379e5dc8bce118d9db18/LOGO_NANO_EXPANDING_LIFE.jpg?locale=de)
Nanobiotix: Statement of Total Voting Rights and Shares Forming the Company’s Share Capital
Regulatory News:
Nanobiotix (Paris:NANO) (NASDAQ:NBTX):
Market: Euronext Paris / Nasdaq
Euronext Compartment: B
ISIN code: FR0011341205
Nasdaq: NBTX
Bloomberg: NANO:FP
Reuters: NANO.PA
Website
![NANOBIOTIX Provides Corporate Update and Highlights Key 2022 Milestone Targets: https://mms.businesswire.com/media/20191111005579/en/744572/5/LOGO_NANO_EXPANDING_LIFE.jpg](https://www.sharewise.com/rails/active_storage/representations/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaHBBM25oRUE9PSIsImV4cCI6bnVsbCwicHVyIjoiYmxvYl9pZCJ9fQ==--fb25377a8ea9e69d3b62f03b482ed70fb95efba1/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaDdCam9MY21WemFYcGxTU0lKTXpVd2VBWTZCa1ZVIiwiZXhwIjpudWxsLCJwdXIiOiJ2YXJpYXRpb24ifX0=--aa36f503a05c343bf077379e5dc8bce118d9db18/LOGO_NANO_EXPANDING_LIFE.jpg?locale=de)
NANOBIOTIX Provides Corporate Update and Highlights Key 2022 Milestone Targets
Regulatory News:
NANOBIOTIX (Euronext: NANO – NASDAQ: NBTX – the ‘‘Company’’), a late-stage clinical biotechnology company pioneering physics-based approaches to expand treatment possibilities
![Transgene Announces Financial Calendar for 2022: https://mms.businesswire.com/media/20191209005543/en/255636/5/logo_TRANSGENE.jpg](https://www.sharewise.com/rails/active_storage/representations/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaHBBOFo2Rmc9PSIsImV4cCI6bnVsbCwicHVyIjoiYmxvYl9pZCJ9fQ==--73fe07bc16ac0607e1cc0e1a0b34e650fa94b07d/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaDdCam9MY21WemFYcGxTU0lKTXpVd2VBWTZCa1ZVIiwiZXhwIjpudWxsLCJwdXIiOiJ2YXJpYXRpb24ifX0=--aa36f503a05c343bf077379e5dc8bce118d9db18/logo_TRANSGENE.jpg?locale=de)
Transgene Announces Financial Calendar for 2022
Regulatory News:
TRANSGENE (Paris: TNG) today announced its financial reporting dates for 2022:
March 16, 2022: 2021 Fiscal Year Results
May 10, 2022: First Quarter 2022 Financial Results
![NANOBIOTIX Announces First Patient Enrolled in NANORAY-312 Global Phase III Registrational Study of NBTXR3 in Head and Neck Cancer: https://mms.businesswire.com/media/20191111005579/en/744572/5/LOGO_NANO_EXPANDING_LIFE.jpg](https://www.sharewise.com/rails/active_storage/representations/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaHBBM25oRUE9PSIsImV4cCI6bnVsbCwicHVyIjoiYmxvYl9pZCJ9fQ==--fb25377a8ea9e69d3b62f03b482ed70fb95efba1/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaDdCam9MY21WemFYcGxTU0lKTXpVd2VBWTZCa1ZVIiwiZXhwIjpudWxsLCJwdXIiOiJ2YXJpYXRpb24ifX0=--aa36f503a05c343bf077379e5dc8bce118d9db18/LOGO_NANO_EXPANDING_LIFE.jpg?locale=de)
NANOBIOTIX Announces First Patient Enrolled in NANORAY-312 Global Phase III Registrational Study of NBTXR3 in Head and Neck Cancer
Regulatory News:
NANOBIOTIX (Euronext: NANO - NASDAQ: NBTX – the “Company”), a late-stage clinical biotechnology company pioneering physics-based approaches to expand treatment possibilities for
![Nanobiotix Announces Participation at Three Virtual Investor Conferences in January 2022: https://mms.businesswire.com/media/20191111005579/en/744572/5/LOGO_NANO_EXPANDING_LIFE.jpg](https://www.sharewise.com/rails/active_storage/representations/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaHBBM25oRUE9PSIsImV4cCI6bnVsbCwicHVyIjoiYmxvYl9pZCJ9fQ==--fb25377a8ea9e69d3b62f03b482ed70fb95efba1/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaDdCam9MY21WemFYcGxTU0lKTXpVd2VBWTZCa1ZVIiwiZXhwIjpudWxsLCJwdXIiOiJ2YXJpYXRpb24ifX0=--aa36f503a05c343bf077379e5dc8bce118d9db18/LOGO_NANO_EXPANDING_LIFE.jpg?locale=de)
Nanobiotix Announces Participation at Three Virtual Investor Conferences in January 2022
Regulatory News:
NANOBIOTIX (Euronext: NANO – NASDAQ: NBTX – the ‘‘Company’’), a late-clinical stage biotechnology company pioneering physics-based approaches to expand treatment possibilities
![Poxel Announces Financial Calendar for 2022: https://mms.businesswire.com/media/20210929005940/en/578635/5/POXEL_LOGO_Q.jpg](https://www.sharewise.com/rails/active_storage/representations/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaHBBOTA1Vnc9PSIsImV4cCI6bnVsbCwicHVyIjoiYmxvYl9pZCJ9fQ==--a443757a54f31cbfc57d9b7b8b30d0d59fbe9bd4/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaDdCam9MY21WemFYcGxTU0lKTXpVd2VBWTZCa1ZVIiwiZXhwIjpudWxsLCJwdXIiOiJ2YXJpYXRpb24ifX0=--aa36f503a05c343bf077379e5dc8bce118d9db18/POXEL_LOGO_Q.jpg?locale=de)
Poxel Announces Financial Calendar for 2022
POXEL SA (Euronext – POXEL - FR0012432516), a clinical stage biopharmaceutical company developing innovative treatments for chronic diseases with metabolic pathophysiology, including non-alcoholic
![ABIONYX Pharma Announces That the French Drug Safety Agency (Agence Nationale de Sécurité du Médicament or ANSM) Has Granted a Compassionate Access Authorization for the bio-HDL (CER-001) in COVID-19 Disease: https://mms.businesswire.com/media/20210302005302/en/862456/5/ABIONYX_W.jpg](https://www.sharewise.com/rails/active_storage/representations/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaHBBM0FtVmc9PSIsImV4cCI6bnVsbCwicHVyIjoiYmxvYl9pZCJ9fQ==--3f52df4b7747dcabeb26ea260ead9545699cca5c/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaDdCam9MY21WemFYcGxTU0lKTXpVd2VBWTZCa1ZVIiwiZXhwIjpudWxsLCJwdXIiOiJ2YXJpYXRpb24ifX0=--aa36f503a05c343bf077379e5dc8bce118d9db18/ABIONYX_W.jpg?locale=de)
ABIONYX Pharma Announces That the French Drug Safety Agency (Agence Nationale de Sécurité du Médicament or ANSM) Has Granted a Compassionate Access Authorization for the bio-HDL (CER-001) in COVID-19 Disease
ABIONYX Pharma (FR0012616852 – ABNX – PEA PME eligible), a new generation biotech company dedicated to the discovery and development of innovative therapies for patients, today announces that the
![Transgene Announces Investor Meetings for January 2022: https://mms.businesswire.com/media/20191209005543/en/255636/5/logo_TRANSGENE.jpg](https://www.sharewise.com/rails/active_storage/representations/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaHBBOFo2Rmc9PSIsImV4cCI6bnVsbCwicHVyIjoiYmxvYl9pZCJ9fQ==--73fe07bc16ac0607e1cc0e1a0b34e650fa94b07d/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaDdCam9MY21WemFYcGxTU0lKTXpVd2VBWTZCa1ZVIiwiZXhwIjpudWxsLCJwdXIiOiJ2YXJpYXRpb24ifX0=--aa36f503a05c343bf077379e5dc8bce118d9db18/logo_TRANSGENE.jpg?locale=de)
Transgene Announces Investor Meetings for January 2022
Regulatory News:
TRANSGENE (Paris:TNG) today announces that Management will participate in the upcoming investor events set out below.
Transgene will meet institutional investors at the 11th
![Transgene announces License Option Exercise by AstraZeneca for an Oncolytic Virus Generated by Transgene’s Invir.IO™ Platform: https://mms.businesswire.com/media/20191209005543/en/255636/5/logo_TRANSGENE.jpg](https://www.sharewise.com/rails/active_storage/representations/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaHBBOFo2Rmc9PSIsImV4cCI6bnVsbCwicHVyIjoiYmxvYl9pZCJ9fQ==--73fe07bc16ac0607e1cc0e1a0b34e650fa94b07d/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaDdCam9MY21WemFYcGxTU0lKTXpVd2VBWTZCa1ZVIiwiZXhwIjpudWxsLCJwdXIiOiJ2YXJpYXRpb24ifX0=--aa36f503a05c343bf077379e5dc8bce118d9db18/logo_TRANSGENE.jpg?locale=de)
Transgene announces License Option Exercise by AstraZeneca for an Oncolytic Virus Generated by Transgene’s Invir.IO™ Platform
Regulatory News:
Transgene (Euronext Paris: TNG) (Paris:TNG), a biotech company that designs and develops virus-based immunotherapeutics against cancer, announces that AstraZeneca
![Poxel Announces its Participation at Upcoming Investor and Scientific Conferences in January 2022: https://mms.businesswire.com/media/20210929005940/en/578635/5/POXEL_LOGO_Q.jpg](https://www.sharewise.com/rails/active_storage/representations/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaHBBOTA1Vnc9PSIsImV4cCI6bnVsbCwicHVyIjoiYmxvYl9pZCJ9fQ==--a443757a54f31cbfc57d9b7b8b30d0d59fbe9bd4/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaDdCam9MY21WemFYcGxTU0lKTXpVd2VBWTZCa1ZVIiwiZXhwIjpudWxsLCJwdXIiOiJ2YXJpYXRpb24ifX0=--aa36f503a05c343bf077379e5dc8bce118d9db18/POXEL_LOGO_Q.jpg?locale=de)
Poxel Announces its Participation at Upcoming Investor and Scientific Conferences in January 2022
POXEL SA (Euronext – POXEL – FR0012432516), a clinical stage biopharmaceutical company developing innovative treatments for chronic serious diseases with metabolic pathophysiology, including